Robertson J S
National Institute for Biological Standards and Control, Herts, UK.
Vaccine. 1994 Dec;12(16):1526-8. doi: 10.1016/0264-410x(94)90077-9.
Whilst it is premature to formulate guidelines for the manufacturing requirements of a nucleic acid vaccine, it can never be too early to discuss and debate the issues surrounding the use of a novel biotherapeutic. The major safety issues posed by nucleic acid vaccination include the possibility of transformation (or tumorigenic) events in recipients of a DNA vaccine, the potential formation of anti-DNA antibodies, and unexpected and untoward effects of long-term expression of a foreign antigen. This paper examines the extent to which these points impinge on the safety of DNA vaccines.
虽然现在制定核酸疫苗生产要求的指南还为时过早,但讨论和辩论围绕新型生物治疗药物使用的问题再早也不为过。核酸疫苗带来的主要安全问题包括DNA疫苗接种者发生转化(或致瘤)事件的可能性、抗DNA抗体的潜在形成,以及外源抗原长期表达的意外和不良影响。本文探讨了这些问题对DNA疫苗安全性的影响程度。